Second malignant neoplasms among long-term survivors of ovarian cancer.
Second malignant neoplasms were evaluated among 32,251 women with ovarian cancer, including 4,402 10-year survivors, within the nine population-based registries of the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute (1973-1992) and the Connecticut Tumor Registry (1935-1972).
Overall, 1,296 second cancers occurred against 1,014 expected [observed/expected (O/E), 1.28 ; 95% confidence interval (CI), 1.21-1.35]. Sites contributing 25 or more excess cancers included leukemia (O/E, 4.17 ; O, 111 ; 95% CI, 3.43-5.03) and malignancies of colon (O/E, 1.33 ; O, 188 ; 95% CI, 1.15-1.54), rectum (O/E, 1.43 ; O, 76 ; 95% CI, 1.13-1.79), breast (O/E, 1.18 ; O, 404 ; 95%, CI 1.07-1.30), and bladder (O/E, 2.07 ; O, 65 ; 95% CI, 1.59-2.63).
Ocular melanoma (O/E, 4.45 ; O, 8 ; 95% CI, 1.92-8.77) was also significantly increased.
Second cancer risk was high during all follow-up intervals, and cumulative risk at 20 years was 18.2%, compared with a population expected risk of 11.5%. Statistically significant relationships existed between serous adenocarcinoma of the ovary and breast cancer (O/E, 1.29 ; 95% CI, 1.06-1.56) and mucinous ovarian adenocarcinoma and rectal cancer (O/E, 1.95 ; 95% CI, 1.09-3.22).
Secondary leukemia appeared linked with antecedent chemotherapy, whereas radiotherapy was associated with cancers of connective tissue, bladder, and possibly pancreas.
Genetic and reproductive factors predisposing to ovarian cancer may h...
Mots-clés Pascal : Survie, Long terme, Second cancer, Tumeur maligne, Ovaire, Homme, Femelle, Facteur risque, Epidémiologie, Connecticut, Etats Unis, Amérique du Nord, Amérique, Localisation, Toxicité, Anticancéreux, Appareil génital femelle pathologie, Ovaire pathologie
Mots-clés Pascal anglais : Survival, Long term, Second cancer, Malignant tumor, Ovary, Human, Female, Risk factor, Epidemiology, Connecticut, United States, North America, America, Localization, Toxicity, Antineoplastic agent, Female genital diseases, Ovarian diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0198252
Code Inist : 002B20E02. Création : 199608.